Sugi Predict

Sugi Predict / Compounds / SCHEMBL2369074

SCHEMBL2369074

SCHEMBL2369074

CCC(O)CNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SYK P43405 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.44
▸ CTSS P25774 5/20 0.44
▸ CTSK P43235 5/20 0.44
▸ APLNR P35414 1/20 0.41
▸ SERPINE1 P05121 1/20 0.40
▸ CA1 P00915 3/20 0.40
▸ CA7 P43166 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CA12 O43570 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5352030 1.00 MEN1 (0.46) MEN1GAAKMT2ASYKTDP1
SCHEMBL12880606 1.00 MEN1 (0.46) MEN1GAAKMT2ASYKTDP1
SCHEMBL570033 0.90 MEN1 (0.50) MEN1GAAKMT2ASYKTDP1
SCHEMBL23314876 0.87 MEN1 (0.45) MEN1GAAKMT2ASYKTDP1
SCHEMBL3683917 0.85 MEN1 (0.47) MEN1GAAKMT2ASYKTDP1
SCHEMBL13960156 0.85 MEN1 (0.46) MEN1GAAKMT2ASYKTDP1
SCHEMBL1222348 0.85 TDP1 (0.49) MEN1GAAKMT2ASYKTDP1
SCHEMBL16379307 0.85 MEN1 (0.46) MEN1GAAKMT2ASYKTDP1
SCHEMBL1222350 0.85 TDP1 (0.49) MEN1GAAKMT2ASYKTDP1
SCHEMBL3166361 0.85 TDP1 (0.49) MEN1GAAKMT2ASYKTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
WO-2025124460-A1 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR 石家庄以岭药业股份有限公司 2025-06-19 — — WO disclosed
WO-2024140851-A1 TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF 上海维申医药有限公司 2024-07-04 — — WO disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
US-11649233-B2 Halo-allylamine SSAO/VAP-1 inhibitor and use thereof NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) 2023-05-16 — — US disclosed
US-20230079863-A1 KHK INHIBITORS GILEAD SCIENCES, INC. 2023-03-16 — — US disclosed
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles BENTLEY JONATHAN M 2005-10-27 — — US disclosed
EP-1325008-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-10-05 — — EP disclosed
US-6933387-B2 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles HOFFMANN-LA ROCHE INC. (US) 2005-08-23 — — US disclosed
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles F. HOFFMANN-LA ROCHE AG (CH) 2003-11-20 — — US disclosed
EP-1325008-A1 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 — — EP disclosed
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) 2002-03-21 — — US disclosed
WO-2002010169-A1 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-07 — — WO disclosed
WO-2000064904-A1 5,7-BICYCLIC AMIDINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2000-11-02 — — WO disclosed
US-4943567-A EFFECTIVE AGAINST PSEUDOMONAS KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-07-24 — — US disclosed
EP-0293771-A2 Cephalosporin compound and pharmaceutical composition thereof Kyoto Pharmaceutical Industries, Ltd. (JP) 1988-12-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles GPR119, INSR, GIPR MEN1 646/4885GAA 3353/4885KMT2A 1434/4885
US-11649233-B2 Halo-allylamine SSAO/VAP-1 inhibitor and use thereof VAPB, VAPA, ADRA1D MEN1 3673/4885GAA 2770/4885KMT2A 4419/4885
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles GPR119, INSR, IRS1 MEN1 901/4885GAA 3048/4885KMT2A 2365/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 MEN1 4138/4885GAA 1454/4885KMT2A 1037/4885
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles GPR119, HTR1D, HTR1A MEN1 1329/4885GAA 1803/4885KMT2A 1282/4885
US-20230079863-A1 KHK INHIBITORS KHK, KHDRBS1, NADK MEN1 2989/4885GAA 1257/4885KMT2A 283/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK MEN1 2989/4885GAA 1257/4885KMT2A 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.